MedTrace Logo

Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma

NCT00425347 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2009-09-23

No results posted yet for this study

Summary

To identify the MTD of HuLuc63 administered intravenously (IV) for 4 doses.2. To evaluate the safety of HuLuc63 IV given every other week for 4 doses.

Conditions

Interventions

DRUG

HuLuc63

Not applicable for HuLuc63.

Sponsors & Collaborators

  • Facet Biotech

    lead INDUSTRY

Principal Investigators

  • William Bensinger, MD · Fred Hutchinson Cancer Center

  • Robert Dean, MD · The Cleveland Clinic

  • Frits van Rhee, M.D. · Arkansas Cancer Research Center

  • Seema Singhal, M.D. · Northwestern University Feinberg School of Medicine

  • Jeffrey A. Zonder, M.D. · Wayne State University

  • Samer Al-Homsi, M.D. · University of Massachusetts Memorial Healthcare

  • Nikhil Munshi, M.D. · Dana-Farber Cancer Institute

  • Ann Mohrbacher, M.D. · USC/Norris Cancer Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2008-08-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00425347 on ClinicalTrials.gov